0001493152-16-012619.txt : 20160817 0001493152-16-012619.hdr.sgml : 20160817 20160817113510 ACCESSION NUMBER: 0001493152-16-012619 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160817 DATE AS OF CHANGE: 20160817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eWELLNESS HEALTHCARE Corp CENTRAL INDEX KEY: 0001550020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 451560906 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55203 FILM NUMBER: 161837882 BUSINESS ADDRESS: STREET 1: 605 WEST KNOX ROAD, SUITE 202 CITY: TEMPE STATE: AZ ZIP: 85284 BUSINESS PHONE: 480-588-3333 MAIL ADDRESS: STREET 1: 605 WEST KNOX ROAD, SUITE 202 CITY: TEMPE STATE: AZ ZIP: 85284 FORMER COMPANY: FORMER CONFORMED NAME: Dignyte, Inc. DATE OF NAME CHANGE: 20120515 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-55203

eWELLNESS HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		45-1560906
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11825 Major Street, Culver City, California		90230
(Address of principal executive offices)		(Zip Code)

(310) 915-9700

(Registrant’s telephone number, including area code)

Copies of Communications to:

Louis Taubman, Esq.

Hunter Taubman Fischer

1450 Broadway, 26^th Floor

New York, NY 10018

P: 917-512-0828

F: 212-202-6380

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]

Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

The number of shares of Common Stock, $0.001 per share par value, outstanding on August 15, 2016 was 19,675,728.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	F-1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3	Quantitative and Qualitative Disclosures About Market Risk	10
Item 4	Controls and Procedures	10
PART II - OTHER INFORMATION
Item 1	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 2	Exhibits	11
Signatures		12

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

eWELLNESS HEALTHCARE CORPORATION

CONDENSED BALANCE SHEETS

		June 30, 2016			December 31, 2015
		(unaudited)

ASSETS

CURRENT ASSETS
Cash	$	12,249		$	41,951
Prepaid Expenses		1,616,202			4,053

Total current assets		2,027,262			46,004

Property & equipment, net		5,122			5,964
Intangible assets, net		18,385			19,862

TOTAL ASSETS	$	1,651,958		$	71,830

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	372,546		$	248,304
Accounts payable - related party		49,702			43,717
Accrued expenses - related party		94,379			33,090
Accrued compensation		850,408			677,000
Contingent liability		90,000			90,000
Convertible debt, net of discount		180,419			309,945
Derivative liability		782,944			2,802
Short term note and liabilities		103,673			71,605

Total current liabilities		2,524,071			1,476,463

Total Liabilities		2,524,071			1,476,463

STOCKHOLDERS’ DEFICIT
Preferred stock, authorized, 10,000,000 shares, $.001 par value, 0 shares issued and outstanding		-			-
Common stock, authorized 100,000,000 shares, $.001 par value, 19,377,770 and 18,170,538 issued and outstanding, respectively		19,378			18,171
Additional paid in capital		4,917,728			2,033,383
Accumulated deficit		(5,809,219	)		(3,456,187	)

Total Stockholders’ Deficit		(872,113	)		(1,404,633	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	1,651,958		$	71,830

The accompanying notes are an integral part of these consolidated financial statements

F-1

eWELLNESS HEALTHCARE CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

For the Three and Six Months ended June 30, 2016 and 2015

(unaudited)

	Three Months Ended						Six Months Ended
	June 30, 2016			June 30, 2015			June 30, 2016			June 30, 2015

OPERATING EXPENSES
Executive compensation		181,367			186,000			372,000			372,000
General and administrative		63,643			62,284			115,169			96,872
Professional fees		727,543			149,668			838,831			240,062

Total Operating Expenses		972,553			397,952			1,326,000			708,934

Loss from Operations		(972,553	)		(397,952	)		(1,326,000	)		(708,934	)

OTHER INCOME (EXPENSE)
Gain on extinguishment of debt		-			-			-			11,323
Loss on derivative liability		(505,142	)		-			(505,142	)		-
Interest expense, related parties		(1,032	)		(879	)		(1,929	)		(1,957	)
Interest expense		(448,697	)		(35,249	)		(519,961	)		(21,391	)

Net Loss before Income Taxes		(1,927,424	)		(434,080	)		(2,353,032	)		(720,959	)

Income tax expense		-			-			-			-

Net Loss	$	(1,927,424	)	$	(434,080	)	$	(2,353,032	)	$	(720,959	)

Basic and diluted (loss) per share	$	(0.10	)	$	(0.03	)	$	(0.12	)	$	(0.04	)

Basic and diluted weighted average shares outstanding		18,671,490			16,881,000			18,986,781			16,811,276

The accompanying notes are an integral part of these consolidated financial statements

F-2

eWELLNESS HEALTHCARE CORPORATION

CONDENSED STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2016 and 2015

(unaudited)

	For Six Months Ended
	June 30, 2016			June 30, 2015

Cash flows from operating activities
Net loss	$	(2,353,032	)	$	(750,959	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,319			2,109
Contributed services		192,000			195,000
Shares issued for consulting services		-			24,222
Imputed interest - related party		1,929			1,956
Options expense		508,395			-
Interest on debt extension		62,933			-
Amortization of debt discount to interest expense		147,650			28,944
Warrants issued for services		-			22,592
Warrants issued for debt extension		780,142			-
Rent contributed by officer		3,000			-
Changes in operating assets and liabilities					-
Advances - related parties		-			7,054
Prepaid expense		127,451			(25,726	)
Accounts payable and accrued expenses		136,829			20,108
Accounts payable - related party		5,985			(10,820	)
Accrued expenses - related party		61,289			24,351
Accrued compensation		173,408			174,000

Net cash used in operating activities		(149,702	)		(287,169	)

Cash flows from investing activities
Purchase of equipment		-			(4,207	)
Net cash used in investing activities		-			(4,207	)

Cash flows from financing activities
Proceeds from issuance of common stock		120,000			270,080
Promissory note		-			25,000

Net cash provided by financing activities		120,000			295,080

Net increase (decrease) in cash		(29,702	)		3,704

Cash, beginning of period		41,951			900

Cash, end of period	$	12,249		$	4,604

Supplemental Information:
Cash paid for:
Taxes	$	-		$	-
Interest Expense	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements

F-3

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Note 1. The Company

The Company and Nature of Business

eWellness Healthcare Corporation (f/k/a Dignyte, Inc.), (the “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has generated no revenues to date. Prior to the Share Exchange Agreement discussed below, other than issuing shares to its original shareholder, the Company never commenced any operational activities.

The eWellness strategy as a first-to-market enterprise in the Physical Therapy based telemedicine industry is to deliver a telemedicine physical therapy service augmenting corporate wellness programs and also expand nationally through a Software as a Service (SaaS) business model that enables existing physical therapy practices to extend their offerings via our telemedicine solution. Our objective is to provide Distance Monitored Physical Therapy (PHZIO) Programs to pre diabetic, cardiac and health challenged patients and knee and hip surgery rehabilitation. For corporate wellness program our services are designed to deliver significant healthcare savings to the company while charging a very small relative incremental cost.

F-4

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The interim financial information of the Company as of and for the periods ended June 30, 2016 and June 30, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

F-5

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Going Concern

sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instruments

As of June 30, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative liability	$	782,944	$	-	$	-	$	782,944
Total liabilities measure at fair value	$	782,944	$	-	$	-	$	782,944

F-6

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Loss per Common Share

The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the period ended June 30, 2016, no dilutive shares are added into the loss per share calculations.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.

F-7

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Note 3. Property and Equipment

Property and equipment consists of computer equipment that is stated at cost $8,421 and $8,421 less accumulated depreciation of $3,299 and $2,457 at June 30, 2016 and December 31, 2015, respectively. Depreciation expense was $842 for the six months ended June 30, 2016 and $632 for the six months ended June 30, 2015, respectively. Depreciation expense was $421 for the three months ended June 30, 2016 and $632 for the three months ended June 30, 2015.

Note 4. Intangible Assets

The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets were $24,770 and $24,770 less accumulated amortization of $6,385 and $4,908 at June 30, 2016 and December 31, 2015, respectively. For the six months ended June 30, 2016 and June 30, 2015, the amortization expense recorded was $1,477 and $1,477, respectively. For the three months ended June 30, 2016 and June 30, 2015, the amortization expense recorded was $739 and $977, respectively.

Note 5. Related Party Transactions

Through the period ended June 30, 2016, a related party, a company for which the Company’s former Secretary-Treasurer and CFO is also serving as CFO, has paid $101,171 on the Company’s behalf for various operating expenses. The amount outstanding as of June 30, 2016 and December 31, 2015 was $49,702 and $43,717, respectively. The Company recorded $1,929 and $1,956 imputed interest on the amount owed to the related party based on an interest rate of 8% for the six months ended June 30, 2016 and June 30, 2015, respectively.

During 2014, the Company entered into a license agreement with a programming company in which one of our directors is Chief Marketing Officer. Through the licensing agreement, we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000. The license fee is recorded as an Intangible Asset and Accounts Payable on the Balance Sheet.

On April 1, 2015, the Company entered into an operating agreement with a physical therapy company (“EPT”) which is owned by the Company’s President and Chief Executive Officer. Through the agreement the Company agrees to provide operating capital advances in order for EPT to offer the Company’s PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPT shall be allocated on a monthly basis. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.

The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Consolidated Statement of Operations and Additional Paid in Capital in the Balance Sheet.

The officers of the Company incur business expenses on behalf of the Company. The amounts outstanding as of June 30, 2016 and December 31, 2015 were $94,379 and $33,090, respectively.

Note 6. Income Taxes

The tax provision for interim periods is determined using an estimate of the Company’s effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.

F-8

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

At June 30, 2016 and December 31, 2015, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.

The Company does not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed. The Company has not had operations and has deferred items consisting entirely of unused Net Operating Losses. Since the Company does not believe that this Net Operating Loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.

The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended June 30, 2016, and June 30, 2015, the Company did not recognize nor accrue for any interest or penalties.

Note 7. Non-Convertible Notes Payable

On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on May 1, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended June 30, 2016, the Company recorded $2,503 of interest expense for this note.

On May 2, 2016, the Company issued a 40-day promissory note to a shareholder of $131,399 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015 and March 14, 2016. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on June 10, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The debt discount calculation for the note resulted in the fair value of the warrants being $1,251,078 and $131,399 being allocated to the note. For the period ended June 30, 2016, the Company recorded $1,641 of interest expense for this note and $118,910 for debt discount interest.

On June 11, 2016, the Company issued a 30-day promissory note to a shareholder of $152,989 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015, March 14, 2016 and May 2, 2016. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on July13, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The debt discount calculation for the note resulted in the fair value of the warrants being $587,780 and $152,988 being allocated to the note. For the period ended June 30, 2016, the Company recorded $1,006 of interest expense for this note and $72,077 for debt discount interest. The note was renewed on July 14, 2016 as discussed in Note 12 – Subsequent Events.

Note 8. Convertible Notes Payable

On February 29, 2016, a convertible promissory note with the principal value of $69,500 was converted to 227,332 shares of common stock at a conversion price of $.35 per share. The warrants associated with this note were not exercised. See Note 9 below – Equity Transactions.

F-9

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

On June 20, 2016, the holder of the promissory note dated December 7, 2015, extended the due date from June 10, 2016 to July 11, 2016. The lender additionally agreed to extend the date required to raise additional capital as set forth in the promissory note to July 11, 2016. In exchange for this extension the Company issued 100,000 warrants to purchase Company common stock at a purchase price of $1.00 per share. The fair value of the warrants is $111,792. The extension also stipulated payment of outstanding interest of $12,000 and extension fee of $13,000. These charges were paid on June 10, 2016. On July 12, 2016, the note was extended as discussed in Note. 12 – Subsequent Events.

Note 9. Equity Transactions

Preferred Stock

The total number of shares of preferred stock which the Company shall have authority to issue is 10,000,000 shares with a par value of $0.001 per share. There have been no preferred shares issued as of June 30, 2016.

Common Stock

The total number of shares of common stock which the Company shall have authority to issue is 100,000,000 shares with a par value of $0.001 per share.

Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders’ meetings for all purposes including the election of directors. The common stock does not have cumulative voting rights.

No holder of shares of stock of any class is entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

On February 29, 2016, the Company authorized the issuance of 227,232 shares for conversion of convertible debt of $69,500.

During the six months ended June 30, 2016, the Company issued 860,000 shares of common stock for consulting services. The weighted average price of these shares was $2.023. The value of the shares are being amortized over the life of the contracts that are from six to twelve months.

F-10

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

On June 2, 2016, the Company sold 120,000 shares of common stock upon receipt of $120,000 cash.

As of the period ended June 30, 2016, the Company has 19,377,770 shares of common stock issued and outstanding.

On February 22, 2016, the Company received the common stock trading symbol of EWLL.

Stock Options

On August 6, 2015, the Board of Directors approved the 2015 Stock Option Plan, pursuant to which certain directors, officers, employees and consultants will be eligible for certain stock options and grants. The Plan is effective as of August 1, 2015 and the maximum number of shares reserved and available for granting awards under the Plan shall be an aggregate of 3,000,000 shares of common stock, provided however that on each January 1, starting with January 1, 2016, an additional number of shares equal to the lesser of (A) 2% of the outstanding number of shares (on a fully-diluted basis) on the immediately preceding December 31 and (B) such lower number of shares as may be determined by the Board or committee charged with administering the plan. This plan may be amended at any time by the Board or appointed plan Committee.

On February 19, 2016, the Board of Directors authorized the issuance of stock options under this plan to selected employees, directors and consultants. The 2,850,000 stock options vest immediately upon the grant date and authorize the recipient to purchase shares of common stock at $.80 per share within five years of the grant date. The Company valued the issuance of these options using the Black Scholes valuation model assuming a .84% risk free rate and 61.4% volatility. At the six months ended June 30, 2016, the vested value of the options was $4,633. This was recorded as compensation expense.

On April 15, 2016, the Board of Directors authorized the issuance of stock options under this plan to a consultant. The 250,000 stock options vested immediately upon the grant date and authorized the recipient to purchase shares of common stock at $1.00 per share within five years of the grant date. The Company valued the issuance of these options using the Black Scholes valuation model assuming a .53% risk free rate and 57.2% volatility. At the six months ended June 30, 2016, the vested value of $503,762 was expensed.

The following is a summary of the status of all Company’s stock options as of June 30, 2016 and changes during the six months ended on that date:

	Number		Weighted
	of Stock		Average
	Options		Exercise Price
Oustanding at January 1, 2016		0	$	-
Granted		3,100,000	$	0.82
Exercised		0	$	-
Cancelled		0	$	-
Outstanding at June 30, 2016		3,100,000	$	0.82
Options exercisable at June 30, 2016		3,100,000	$	0.82

F-11

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Warrants

On June 2, 2016, the Company authorized the issuance of 60,000 warrants that were issued as part of a stock purchase agreement for $120,000.

On June 10, 2016, the Company authorized the issuance of 100,000 warrants that were issued as part of the extension of a convertible note dated December 7, 2015. The fair value of the warrants is $111,792.

During the six months ended June 30, 2016, the Company issued 1,200,000 warrants as part of the extensions of promissory notes dated December 15, 2014, March 14, 2016 and May 1, 2016. The fair value of all warrants is $1,839,652.

The following is a summary of the status of all of the Company’s warrants as of June 30, 2016 and changes during the six months ended on that date:

			Weighted
	Number of		Average
	Warrants		Exercise Price
Outstanding at January 1, 2015		609,533	$	0.35
Granted		5,021,658	$	0.63
Exercised		-	$	-
Cancelled		-	$	-
Outstanding at December 31, 2015		5,631,191	$	0.61
Granted		1,360,000	$	0.85
Exercised		-	$	-
Cancelled		-	$	-
Outstanding at June 30, 2016		6,991,191	$	0.65

For purpose of determining the fair market value of the warrants issued during the six months ended June 30, 2016, we used the Black Scholes option valuation model. These valuations were done throughout the period at the date of issuance and not necessarily as of the reporting date. The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:

Stock price on the valuation date	$	2.00-3.75
Exercise price of warrants	$	.80 and 1.00
Dividend yield		0.00	%
Years to maturity		1-5
Risk free rate		1.06%-1.32	%
Expected volatility		61.41%-63.40	%

F-12

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

Note 10. Commitments, Contingencies

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.

The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (“Rule 419”) of Regulation C under the Securities Act of 1933, as amended (the “Securities Act”) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a “Blank Check” offering subject to Rule 419 (the “Rule 419 Offering”) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the “Trust Account Balance”).

Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all of the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.

Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company’s restricted common stock in the Converted Offering (the “Consent”) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.

However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust accountshall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.

F-13

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.

As a result of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. As a result of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.

Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining at this time the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. In light of the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent.

The Company rents its Culver City, CA office space from a company owned by our CEO. The rental agreement provides for the value of the rent of $500 per month be recorded as contributed towards the founding eWellness and its operations. During the period ended June 30, 2016, we have recorded this rent payment in the Consolidated Statements of Operations and Additional Paid in Capital on the Balance Sheet.

On April 1, 2015, the Company entered into an Operating Agreement with Evolution Physical Therapy (“EPT”), a company owned by one of the Company’s officers, wherein it is agreed that EPT would be able to operate the Company’s telemedicine platform www.phzio.com and offer it to selected physical therapy patients of EPT. The Company is to receive 75% of the net insurance reimbursements from the patient for use of the platform. The Company will advance capital requested by EPT for costs specifically associated with operating the www.phzio,com platform and associated physical therapy treatments – computer equipment, office or facilities rental payments, physical therapist or physical therapy assistant, administrative staff, patient induction equipment, office supplies, utilities and other associated operating costs. It is anticipated that the operation of the platform by EPT will generate positive cash flow within 90 days from the start of patient induction.

F-14

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

On May 20, 2015, the Company entered into an agreement with Mavericks Capital Securities LLC (“Mavericks”). The term of the contract begins on the effective date and can be terminated within 30 days upon written notice by either party. The Company is to pay Mavericks a monthly retainer fee of $10,000 that is deferred until the Company raises $250,000 in new investor funds from the effective date. In addition, the Company granted Mavericks 250,000 warrants to purchase Company common stock at $.35 per share. On September 28, 2015, the Company and Mavericks entered into an amendment to the consultant agreement pursuant to which Mavericks will also assist the Company in the acquisition of new customers, for which the Company shall pay Mavericks 10% of the revenue received by the Company, net of any pass through costs, from any such customers introduced to the Company by Mavericks; payment shall be made upon the Company’s receipt of such revenues. In the amendment, the parties also further clarified the definition of Customer Acquisition.

On January 20, 2016, the Company entered into a one year agreement with a consulting firm to provide marketing and financial media awareness services. Compensation for this agreement is the issuance of 100,000 shares of common stock – 50,000 were issued at the signing of the agreement and the other 50,000 are to be issued in July, 2016. As of the filing of this report, these shares have not been issued. The value of these shares is $5,000 for each issuance which is being amortized over the term of the contract.

On February 1, 2016, the Company entered into a six month agreement with a consulting firm for services including introductions to brokers, investment bankers, market makers and business development opportunities. Compensation for his agreement is the issuance of 100,000 shares of common stock. The value of these shares is $10,000 and is being amortized over the term of the contract.

On March 3, 2016, the Company entered into a six month agreement with a consulting firm for management consulting, business advisory and public relations services. Compensation for this agreement is the issuance of 100,000 shares of common stock for the purchase price of $100 and a $2,500 monthly fee that is to be accrued and not payable until the Company closes a qualified financing.

On April 13, 2016, we entered into a one-year renewable advisory agreement with Dan Mills, MPT to become the Company’s chairman of the to-be-formed committee known as the eWellness Physical Therapy Clinical Advisory Board and to act as the Company’s national spokesperson at the American Physical Therapy Association (“APTA”).

As inducement for Mr. Mills to enter the Agreement, we agreed to issue 250,000 immediately vesting common stock purchase warrants at a price of $1.00 per share. The fair value of the warrants is $503,762. The common stock underlying the warrants has piggy-back registration rights. In addition, 10,000 shares of common stock were issued with a value of $30,000. Per the agreement Mr. Mills will receive $0.50 cents per PHZIO session that an APTA members uses and $500 per month in consulting fees.

F-15

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

On May 23, 2016, the Company entered into a one-year agreement with a financial advisory consultant. Compensation for this agreement is the issuance of 450,000 shares of common stock that vest on January 2, 2017. The value of these shares is $1,669,500 and is being amortized over the term of the contact.

From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, the Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Note 11. Derivative Valuation

The warrants granted with the $275,000 senior convertible promissory note (the “Note”) issued on December 7, 2015 (described in Note 8) have a Most Favored Nation clause resulting in the exercise price of the warrants not being fixed. Therefore, this feature has been characterized as a derivate liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. During the three and six months ended June 30, 2016, the outstanding fair value of the warrants accounted for as a derivative liability amounted to $782,944. As of June 30, 2016, a loss of $505,142 was recognized in the statement of operations as the change in valuation from inception.

For purposes of determining the fair market value of the derivative liability for the warrants and the convertible note, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

Stock price at valuation date	$	1.75
Exercise price of warrants	$	0.75-1.00
Risk free interest rate		0.2-1.01	%
Stock volatility factor		49.70-62.65	%
Years to Maturity		.03-4.44
Expected dividend yield		None

Note 12. Subsequent Events

On July 5, 2016, the Company entered into a six-month agreement with an investment and business consultant for certain investment and business matters. Compensation for this agreement is the issuance of 125,000 shares of common stock.

F-16

eWellness Healthcare Corporation

Notes to Condensed Financial Statements

(unaudited)

On July 8, 2016, the Company entered into a five year business development agreement with a consultant for marketing the Company’s telemedicine platform to its customers. Upon the completion of a partnership for the Company with a large scale California employer and/or one of its affiliate institutions that includes at least a 100 patient pilot study, the Company agrees to issue 50,000 $1.00 common stock 5-year purchase warrants. For each additional licensing of 20 physical therapy professionals through the consultant, the Company will issue an additional 50,000 common stock 5-year purchase warrants priced at market at the time of issuance. For any direct investor introduced by the consultant, the Company will pay a 5% cash fee on the gross amount invested.

On July 12, 2016, the Company agreed to an extension on a promissory note dated December 7, 2015. As an inducement for the extension of this note, the Company agreed to pay a $10,000 loan extension fee and issue 300,000 warrants to purchase Company common stock at $.50 per share.

On July 13, 2016, the Company issued 172,958 shares of common stock as a result of warrants being exercised.

On July 13, 2016, the Company agreed to amend certain previous warrants granted on August 28, 2015, September 16, 2015, October 3, 2015, December 6, 2015, March 14, 2016, May 1, 2016, and June 20, 2016. The previously granted warrants had a purchase price of $.80 per share and the Company has agreed to reduce that to $.50 per share. Amendments for these warrants were issued.

On July 14, 2016, the Company issued a 30-day promissory note to a shareholder of $177,762 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015, March 14, 2016, May 2, 2016, and June 11, 2016. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on August 15, 2016. As an inducement for this promissory note, the Company issued 300,000 warrants to purchase Company common stock at $.50 per share.

F-17

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including but not limited to: variability of our future revenues and financial performance; risks associated with product development and technological changes; the acceptance of our products in the marketplace by potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the financial statements of eWellness Healthcare Corporation for the three and six months ended June 30, 2016 and 2015 and should be read in conjunction with such financial statements and related notes included in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

THE COMPANY

Business Overview

Our business model is to license our PHZIO (“PHZIO”) telemedicine platform to any physical therapy (“PT”) clinic in the U.S. and or have large-scale employers use our PHZIO platform as a fully PT monitored corporate wellness program.

As shown in the financial statements accompanying this Quarterly Report, the Company has had no revenues to date and has incurred only losses since its inception. The Company has operations currently only in Culver City, California and has been issued a “going concern” opinion from our accountants, based upon the Company’s reliance upon the sale of our common stock as the sole source of funds for our future operations.

The Company’s operations and corporate offices are located at 11825 Major Street Culver City, CA, 90230, with a telephone number of (310) 915-9700.

The Company’s fiscal year end is December 31.

Plan of Operations

The Company’s initial licensee is Evolution Physical Therapy (“EPT”), which is owned by our CEO, Darwin Fogt, MPT. Treatment revenue for the first six months of 2016 was retained by EPT for expenses so no revenue was generated for the Company. The Company is in the process of developing marketing channel partnerships with industry association members, existing software-based telemedicine providers and physical therapy billing and practice management providers. These Software as Service (“SaaS”) licenses to third party physical therapy clinic and these other partnerships, if completed, are anticipated to begin adding third party PT licensee revenue during the third or fourth quarters of 2016.

The Company’s PHZIO home physical therapy exercise platform has been designed to disrupt the $30 billion physical therapy and the $8 billion corporate wellness industries. PHZIO re-defines the way physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many physical therapy platform for home use. Due to the real-time patient monitoring feature, the PHZIO platform is insurance reimbursable by payers such as: Anthem Blue Cross and Blue Shield.

The PHZIO Solution: A New Physical Therapy Delivery System

	●	SaaS technology platform solution for providers bundling rehabilitation services and employer wellness programs;

	●	First real-time remote monitored 1-to-many physical therapy treatment platform for home use;

	●	Ability for physical therapists to observe multiple patients simultaneously in real-time;

	●	Solves what has been a structural problem and limitation in post-acute care practice growth.

	●	Based on the Company’s experience, PT practices can experience 20% higher adherence & compliance rates versus industry standards; and

	●	Based on the Company’s experience, we have tracked a 30% increase in net income for a PT practice.

Based on the Company’s experience, patient program adherence in 2015 and the first half of 2016 was nearly 85 percent due to the real-time patient monitoring and the at-home use of the platform. Now physical therapy practices have a way to scale profitably using a technology platform that can help them grow beyond the limits of the typical brick and mortar PT clinic.

Additional Treatment Protocols: The Company’s initial PHZIO application is a 6-month exercise program for patients with back, knee or hip pain. The next two platforms are anticipated to be released in the third quarter of 2016 include a total knee and hip replacement exercise program. These hip and knee programs have been designed to be integrated into any hospital or medical group’s Medicare CMS bundled payment model for post-acute care physical therapy. These two programs are anticipated to be followed by woman’s health and geriatric programs by the end of the fourth quarter of 2016.

Our PHZIO platform enables employees or patients to engage with live or on-demand video based physical therapy telemedicine treatments from their home or office. Following a physician’s exam and prescription for physical therapy to treat back, knee or hip pain, a patient can be examined by a physical therapist and, if found appropriate, inducted in the Company’s PHZIO program that includes a progressive 6-month telemedicine exercise program (including monthly in-clinic checkups). All PHZIO treatments are monitored by a licensed therapist that sees everything the patient is doing while providing their professional guidance and feedback in real-time. This ensures treatment compliance by the patient, maintains the safety and integrity of the prescribed exercises, tracks patient metrics and captures pre and post treatment evaluation data. PHZIO unlocks a host of potential for revolutionizing patient treatment models and directly links back to the established brick and mortar physical therapy clinic. This unique model enables any physical therapy practice to be able to execute more patient care while utilizing their same resources, and creates more value than was ever before possible.

During 2015 and the first half of 2016 our PHZIO platform achieved the following metrics:

	●	The total monitored PHZIO patient visits was approximately 1,200 .

	●	The average insurance reimbursement per PHZIO session in 2015: $46.87 (excluding co-payments).

	●	Based on the Company’s experience, the top line wellness goals of our PHZIO program are to graduate at least 80% of inducted patients through our 6-month program. Patients should expect to experience an average of a 20% reduction in BMI, a 4-inch reduction in waist size, weight loss of at least 20 pounds, significant overall improvement in balance, coordination, flexibility, strength, and lumbopelvic stability. Patients also should score better on Functional Outcomes Scales (Oswestry and LEFS), which indicates improved functional activity levels due to reduced low back, knee and hip pain.

2016 PHZIO Customer Acquisition & Sales Goals

On September 6, 2016, we plan to commercially launch the licensing of our PHZIO platform to 3^rd party physical therapy practices throughout the U.S.

The American Physical Therapy Association (APTA), Private Practice Section (PPS) members are our initial universe of PT practices to target. Our sale launch begins with full-page print advertising in the PT industry's premier magazine Impact in early September 2016. It is then to be followed up with a full-page ad in the APTA PPS Conference Buyers Guide in early October. Following these two print advertisements, we will also be a tier 1 sponsor at the PPS Las Vegas conference from October 19-22, 2016 (October 20^thLunch Sponsor and 4-6pm Cocktail Reception Sponsor & Exclusive PHZIO Demo Session for all attendees). PHZIO will also have a full-page ad included in November 2016 and January 2017 Impact magazine issues. Our 2016 Customer Acquisition & Sales goals are to on-board at least 35 third-party PT practices during the 3^rd and 4^thquarter of 2016. Each on-boarded PT practice will have a goal of inducting at least 3 new patients per week onto our PHZIO platform with a goal of delivering at least 17,000 PHZIO exercise session in the second half of 2016. Based upon achieving this number of PHZIO sessions, it would generate approximately $344,000 in gross revenue for the Company, during the second half of 2016. Our planned sales launch includes industry advertising, lead generation and qualification program, which is anticipated to be implemented through a strategic partnership with a US-based sales support organization through a revenue share agreement. Our customer acquisition and sales strategy includes:

Lead Generation and Qualification through a call center that utilizes well-designed program stimuli and tactics, as well as strong agent lead qualification and closing skills. Next, based upon advertising to the PPS membership, we also plan to include an Inbound Sales team to handle virtually any type of inbound hard-or soft-sell sales call that embodies a sales performance-based culture. Our strategic partner will not be a typical script-driven order taking call center, they will embrace the natural dialogue and relationship skills necessary to turn every contact opportunity into a sale. Lastly, we anticipate an Outbound Sales to the PPS membership through mail, phone and e-mail, will be handled within the confines of privacy laws and regulations, where we anticipate creating an effective vehicles for gathering customer information, bringing awareness to discounts or promotions, and serving as a proactive retention tool for valued customers.

Customer Relationship Management (CRM)

We will also be implementing a CRM that provides practices, strategies and technologies that we will use to manage and analyze customer interactions and data throughout the customer lifecycle, with the goal of improving business relationships with customers, assisting in customer retention and driving sales growth. CRM systems are designed to compile information on customers across different channels — or points of contact between the customer and the company — which could include the company’s website, telephone, live chat, direct mail, marketing materials and social media. CRM systems can also give customer-facing staff detailed information on customers’ personal information, purchase history, buying preferences and concerns.

Our PHZIO platform, including: design, testing, exercise intervention, follow-up, and exercise demonstration, has been developed by accomplished Los Angeles based physical therapist Darwin Fogt. Mr. Fogt has extensive experience and education working with diverse populations from professional athletes to morbidly obese. He understands the most beneficial exercise prescription to achieve optimal results and has had great success in motivating all patient types to stay consistent in working toward their goals. Additionally, his methods have proven effective and safe as he demonstrates exercises with attention to proper form to avoid injury. Mr. Fogt has established himself as a national leader in his field and has successfully implemented progressive solutions to delivering physical therapy: he has consulted with and been published by numerous national publications including Runner’s World, Men’s Health, Men’s Journal, and various Physical Therapy specific magazines; his 13 plus years of experience include rehabilitating the general population, as well as professional athletes, Olympic gold medalists, and celebrities. He has bridged the gap between physical therapy and fitness by opening Evolution Fitness, which uses licensed physical therapists to teach high intensity circuit training fitness classes. He also founded one of the first exclusive prenatal and postnatal physical therapy clinics in the country. Mr. Fogt is a leader in advancing the profession to incorporate research-based methods and focus on, not only rehabilitation but also wellness, functional fitness, performance, and prevention. He is able to recognize that the national healthcare structure (federal and private insurance) is moving toward a model of prevention and that the physical therapy profession will take a larger role in providing wellness services to patients.

Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current access to physical therapy clinics.

Our underlying technology platform is complex, deeply integrated and purpose-built over the three years for the evolving physical therapy marketplace. Our PHZIO platform is highly scalable and can support substantial growth of third party licensees. Our PHZIO platform provides for broad interconnectivity between PT practitioners and their patients and, we believe, uniquely positions us as a focal point in the rapidly evolving PT industry to introduce innovative, technology-based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home care.

We plan to generate revenue from third-party PT and corporate wellness licensees on a contractually recurring per PHZIO session fee basis. Our PHZIO platform is anticipated to transform the access, cost and quality dynamics of physical therapy delivery for all of the market participants. We further believe any patient, employer, health plan or healthcare professional interested in a better approach to physical therapy is a potential PHZIO platform user.

We have developed various key performance indicators that we anticipate using to assess our business after we on-board third party PT licensees later in the year.

Before even launching, we have received a high indication of interest in our service. We think the demand is warranted, but recognize that in the early stages of our services, we may experience bottlenecks in our ability to meet the demand for same. Under this type of environment it is critical to maintain awareness of the Company’s operational budget goals and how they are being met in our attempts to address demand. Because the Company is “early stage” and launching with a minimum of capital, monitoring cash flow on a constant basis will be essential to growth.

During the third quarter of 2015, we pivoted our business model to focus on licensing our PHZIO platform to any physical therapy clinics in the U.S. and or to have large scale employers use our platform as a corporate wellness program. The Physical Therapy industry has remained disconnected and unscalable throughout the technological revolution of the past twenty years. Over 200,000 Physical Therapists are limited to one-on-one patient treatments within a traditional clinic setting. The Physical Therapy industry measures $33 Billion in size with over 270 Million one-on-one treatments delivered annually. This technology gap and market size is the opportunity that the Company is focused on with the recent launch of its PHZIO telemedicine platform.^[1]

¹Sources: Harris Williams & Co., Physical Therapy Market Overview, Feb 2014 IBIS World, Physical Therapists in the US (Report 62134), May 2015

Our PHZIO platform enables patients to engage with live or on-demand video based physical therapy telemedicine treatments from their home or office. Following a physician’s exam and prescription for physical therapy to treat back, knee or hip pain, a patient can be examined by a physical therapist and if found appropriate inducted in eWellness’ PHZIO program that includes a progressive 6-month telemedicine exercise program (including weekly in-clinic exercise sessions and monthly in-clinic checkups. All PHZIO treatments are monitored by a licensed therapist that sees everything the patient is doing while providing their professional guidance and feedback in real-time. This ensures treatment compliance by the patient, maintains the safety and integrity of the prescribed exercises, tracks patient metrics and captures pre and post treatment evaluation data. PHZIO unlocks a host of potential for revolutionizing patient treatment models and directly links back to the established brick and mortar Physical Therapy clinic. This unique model enables any physical therapy practice to be able to execute more patient care while utilizing their same resources, and creates more value than was ever before possible.

Through our Cooperative Operating Agreement with Evolution Physical Therapy (“EPT”) their Marina del Rey, California patient induction office (“PIO”) is effectively a laboratory for us to support the licensing of our platform to the entire Physical Therapy (“PT”) industry. In April we moved the PIO to EPT’s Culver City location as we could not extend the lease at that location. Active PT licensing of our PHZIO platform is anticipated to begin in the third quarter of 2016. We have also developed a separate vertical for our PHZIO platform that focuses on the marketing of our platform as a robust Corporate Wellness program. Active marketing to the large scale employers in the Los Angeles area began in the October 2015 with the first corporate wellness program first pilot program with a Los Angeles based university commencing in the second quarter of 2016.

We are also actively seeking corporate partnership relationships with other telemedicine companies that if completed, would create a new channel for our corporate wellness PHZIO program. Amid ongoing challenges and changes within the healthcare industry, telemedicine is emerging as an increasingly attractive tool for delivering quality medical & wellness services.

In early 2016, we began offering our PHZIO program that has been designed to be the most productive physical exercise program available to corporate wellness programs and their employees. We anticipate that employers using our system can significantly improve employee wellness and decrease costs associated with workman’s compensation claims. PHZIO is a comprehensive lifestyle management intervention. Our PHZIO exercise program documents an employee’s success or failure. We can provision highly reliable Return On Investment (“ROI”) metrics displayed on an easy to use HIPAA compliant dashboard for any organization using our PHZIO system.

The Current State of Workplace Wellness Programs:

Broadly, a workplace wellness program is an employment-based activity or employer-sponsored benefit aimed at promoting health-related behaviors (primary prevention or health promotion) and disease management (secondary prevention). It may include a combination of data collection on employee health risks and population-based strategies paired with individually focused interventions to reduce those risks. A formal and universally accepted definition of a workplace wellness program has yet to emerge, and employers define and manage their programs differently. Programs may be part of a group health plan or be offered outside of that context; they may range from narrow offerings, such as free gym memberships, to comprehensive counseling and lifestyle management interventions⁴.

Wellness programs have become very common, as 92 percent of employers with 200 or more employees reported offering them in 2009. Survey data indicate that the most frequently targeted behaviors are exercise, addressed by 63 percent of employers with programs; smoking (60 percent); and weight loss (53 percent). In spite of widespread availability, the actual participation of employees in such programs remains limited. While no nationally representative data exist, a 2010 non-representative survey suggests that typically fewer than 20 percent of eligible employees participate in wellness interventions.

Wellness Program Impact: In industry surveys, employers typically express their conviction that workplace wellness programs are delivering on their promise to improve health and reduce costs. Numerous anecdotal accounts of positive program effects are consistent with this optimistic view. Further, several evaluations of individual programs and summative reviews in the scientific literature provide corroborating evidence for a positive impact.

In “A Review of the U.S. Workplace Wellness Market “, the most recent scientific literature evaluating the impact of workplace wellness programs on health-related behavior and medical cost outcomes identified 33 peer-reviewed publications that met their standards for methodological rigor. They found, consistent with previous reviews, evidence for positive effects on diet, exercise, smoking, alcohol use, physiologic markers, and health care costs, but limited evidence for effects on absenteeism and mental health. They could not conclusively determine whether or not program intensity was positively correlated with impact. Positive results found in this and other studies should be interpreted with caution, as many of these programs were not evaluated with a rigorous approach, and published results may not be representative of the typical experience of a U.S. employer.

The Company completed the initial closing of a private financing of up to $120,000 in June, 2016, pursuant to Rule 506 (c) promulgated pursuant to the Securities Act of 1933, as amended.

Results of Operations for the three and six months ended June 30, 2016 and June 30, 2015.

The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this Quarterly Report.

Operating Expenses

Operating expenses for the three months ended June 30, 2016 and June 30, 2015 were $972,553 and $397,952, respectively. Operating expenses during the six months ended June 30, 2016 and June 30, 2015 were $1,326,000 and $708,934, respectively. Operating expenses increased for the six and three month periods primarily as a result of an increase in professional fees for consulting services.

Interest Expense.

Interest expense, including interest expense-related parties, was $449,729 and $36,158, for the three months ended June 30, 2016 and June 30, 2015, respectively. Interest expense, including interest expense–related parties, was $521,890 and $23,348 for the six months ended June 30, 2016 and June 30, 2015, respectively. The increase was related to costs of convertible debt with unrelated parties.

Net Loss

Net loss during the three months ended June 30, 2016 and June 30, 2015 was $1,927,424 and $434,080, respectively. Net loss during the six months ended June 30, 2016 and June 30, 2015 totaled $2,353,032 and $720,959, respectively. The increase in the net loss is a result of increased operating expenses and interest expense as discussed above.

Liquidity and Capital Resources

The Company had $12,249 and $41,951 cash as of June 30, 2016 and December 31, 2015, respectively.

Net cash used in operating activities was $149,702 for the six months ended June 30, 2016, compared to $287,169 for the six months ended June 30, 2015.

Net cash used in investing activities was $0 for the six months ended June 30, 2016, compared to $4,207 for the six months ended June 30, 2015.

Net cash provided by financing activities during the six months ended June 30, 2016, was $120,000 compared to $295,080 for the six months ended June 30, 2015.

We had not yet earned any revenues during the period ended June 30, 2016. Our current cash position is not sufficient to fund our cash requirements during the next twelve months including operations and capital expenditures. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

We had assets at June 30, 2016 of $2,050,769. We will be reliant upon shareholder loans, private placements or public offerings of equity to fund any kind of operations, although there can be no guarantee we will be able to secure such finding on beneficial terms, if at all. We have secured no sources of loans.

Contingencies

However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.

As disclosed in the prior amendments to the Initial Form 8-K, we have filed the prior amendments in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to the Company’s potential violation of Rule 419. Although the Company has continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, based upon latest communications with the persons reviewing the Form 8-K, they do not agree with the assessments the Company presented to them. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2015, for disclosures regarding the Company’s critical accounting policies and estimates, as well as any updates further disclosed in our interim financial statements as described in this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company”, we are not required to provide the information under Item 3.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on that evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2016, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules, regulations and forms, and (ii) that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Controls Over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On April 15, 2016, the Company authorized the issuance of 10,000 shares for consulting services for a value of $30,000.

On May 17, 2016, the Company authorized the issuance of 100,000 shares for consulting services for a value of $10,000.

On May 23, 2016, the Company authorized the issuance of 450,000 shares for consulting services for a value of $1,669,500.

On June 2, 2016, the Company sold 120,000 shares for $120,000 cash.

As of the period ended June 30, 2016, the Company has 19,377,770 shares of common stock issued and outstanding.

All of the transactions listed above were made pursuant to the exemption from the registration provisions of the Securities Act of 1933, as amended, provided by Section 4(a)(2) of the Securities Act for sales not involving a public offering or Rule 506(b) of Regulation D promulgated by the SEC. The securities issued have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

ITEM 6. EXHIBITS.

Exhibit No.		Description
3.1		Amended & Restated Certificate of Incorporation of Registrant. (Incorporated by reference to Exhibit 4.1 to the Form 8-K/A filed on August 6, 2014)

3.2		Bylaws of the Company. (Incorporated by reference to Exhibit 3(b) to the Registration Statement on Form S-1 filed on May 15, 2012)

10.1		Securities Purchase Agreement dated December 23, 2014 (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)

10.2		Form of 12% Senior Convertible Promissory Note (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)

10.3		Form of Series A Warrant Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)

10.4		Form of Registration Rights Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)

10.5		Form of Security Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 6, 2015)

10.6		Operating Agreement with Evolution Physical Therapy (Incorporated by reference to Exhibit 10.6 of the Company’s Quarterly Report on Form 10-Q filed on May 12, 2015)

10.7		Medical Advisory Agreement with Akash Bajaj M.D., M.P.H. (Incorporated by reference to Exhibit 10.7 of the Company’s Quarterly Report on Form 10-Q filed on May 12, 2015)
10.8		Advisory Agreement *
31.1		Rule 13a-14(a)/15d-14(a) Principal Executive Officer Certification*

31.2		Rule 13a-14(a)/15d-14(a) Principal Financial and Accounting Officer Certification*

32.1		Certifications under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)*

32.2		Certification under Section 906 of the Sarbanes-Oxley Act (18 U.S.C. Section 1350)*

101.INS		XBRL INSTANCE DOCUMENT *

101.SCH		XBRL TAXONOMY EXTENSION SCHEMA *

101.CAL		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE *

101.DEF		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE *

101.LAB		XBRL TAXONOMY EXTENSION LABEL LINKBASE *

101.PRE		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE *

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	eWellness Healthcare Corporation

Date: August 17, 2016	By:	/s/ Darwin Fogt
		Darwin Fogt
		Director and Chief Executive Officer
		(Principal Executive Officer)

Date: August 17, 2016	By:	/s/ David Markowski
		David Markowski, Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

Exhibit 31.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Darwin Fogt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016 of eWellness Healthcare Corporation (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 17, 2016

/s/ Darwin Fogt
Darwin Fogt,
Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

Exhibit 31.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David Markowski, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016 of eWellness Healthcare Corporation (the “registrant”);

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 17, 2016

/s/ David Markowski
David Markowski,
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

Exhibit 32.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended June 30, 2016 as filed with the Securities and Exchange Commission (the “Report”), the undersigned Darwin Fogt, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	eWellness Healthcare Corporation.

Date: August 17, 2016	By:	/s/ Darwin Fogt
		Darwin Fogt, Director and Chief Executive Officer
		(Principal Executive Officer)

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

Exhibit 32.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended June 30, 2016 as filed with the Securities and Exchange Commission (the “Report”), the undersigned David Markowski, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	eWellness Healthcare Corporation

Date: August 17, 2016	/s/ David Markowski
	David Markowski, Chief Financial Officer
	(Principal Financial and Accounting Officer)

0.10 0.90 eWELLNESS HEALTHCARE Corp 10-Q 2016-06-30 false --12-31 Q2

Smaller Reporting Company

400000 400000 400000 .80 .80 .80

The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock price on the valuation date</td> <td> </td> <td>$</td> <td style="text-align: right">2.00-3.75 </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise price of warrants</td> <td> </td> <td>$</td> <td style="text-align: right">.80 and 1.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Dividend yield</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">0.00</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Years to maturity</td> <td> </td> <td> </td> <td style="text-align: right">1-5 </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free rate</td> <td> </td> <td> </td> <td style="text-align: right">1.06%-1.32</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">61.41%-63.40</td> <td>%</td></tr> </table>

The significant assumptions used in the Black Scholes valuation of the derivative are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Stock price at valuation date</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">1.75</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise price of warrants</td> <td> </td> <td>$</td> <td style="text-align: right">0.75-1.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.2-1.01</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock volatility factor</td> <td> </td> <td> </td> <td style="text-align: right">49.70-62.65</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Years to Maturity</td> <td> </td> <td> </td> <td style="text-align: right">.03-4.44 </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">None </td> <td> </td></tr> </table>

250000 250000 50000 300000 300000

50000 P5Y 172958 On July 13, 2016, the Company agreed to amend certain previous warrants granted on August 28, 2015, September 16, 2015, October 3, 2015, December 6, 2015, March 14, 2016, May 1, 2016, and June 20, 2016 2016 EWLL

Note 1. The Company   The Company and Nature of Business   eWellness Healthcare Corporation (f/k/a Dignyte, Inc.), (the Company, we, us, our) was incorporated in the State of Nevada on April 7, 2011, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has generated no revenues to date. Prior to the Share Exchange Agreement discussed below, other than issuing shares to its original shareholder, the Company never commenced any operational activities.   The eWellness strategy as a first-to-market enterprise in the Physical Therapy based telemedicine industry is to deliver a telemedicine physical therapy service augmenting corporate wellness programs and also expand nationally through a Software as a Service (SaaS) business model that enables existing physical therapy practices to extend their offerings via our telemedicine solution. Our objective is to provide Distance Monitored Physical Therapy (PHZIO) Programs to pre diabetic, cardiac and health challenged patients and knee and hip surgery rehabilitation. For corporate wellness program our services are designed to deliver significant healthcare savings to the company while charging a very small relative incremental cost.

Note 3. Property and Equipment   Property and equipment consists of computer equipment that is stated at cost $8,421 and $8,421 less accumulated depreciation of $3,299 and $2,457 at June 30, 2016 and December 31, 2015, respectively. Depreciation expense was $842 for the six months ended June 30, 2016 and $632 for the six months ended June 30, 2015, respectively. Depreciation expense was $421 for the three months ended June 30, 2016 and $632 for the three months ended June 30, 2015.

Note 4. Intangible Assets   The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets were $24,770 and $24,770 less accumulated amortization of $6,385 and $4,908 at June 30, 2016 and December 31, 2015, respectively. For the six months ended June 30, 2016 and June 30, 2015, the amortization expense recorded was $1,477 and $1,477, respectively. For the three months ended June 30, 2016 and June 30, 2015, the amortization expense recorded was $739 and $977, respectively.

Note 5. Related Party Transactions   Through the period ended June 30, 2016, a related party, a company for which the Companys former Secretary-Treasurer and CFO is also serving as CFO, has paid $101,171 on the Companys behalf for various operating expenses. The amount outstanding as of June 30, 2016 and December 31, 2015 was $49,702 and $43,717, respectively. The Company recorded $1,929 and $1,956 imputed interest on the amount owed to the related party based on an interest rate of 8% for the six months ended June 30, 2016 and June 30, 2015, respectively.   During 2014, the Company entered into a license agreement with a programming company in which one of our directors is Chief Marketing Officer. Through the licensing agreement, we obtained a perpetual license to use the programming code created by a video management platform as a base to develop our telemedicine video service for a license fee of $20,000. The license fee is recorded as an Intangible Asset and Accounts Payable on the Balance Sheet.   On April 1, 2015, the Company entered into an operating agreement with a physical therapy company (EPT) which is owned by the Companys President and Chief Executive Officer. Through the agreement the Company agrees to provide operating capital advances in order for EPT to offer the Companys PHIZIO platform to physical therapy patients. For accounting and tax purposes, the net profits or losses generated by EPT shall be allocated on a monthly basis. The Company will receive 75% of the net patient insurance reimbursements associated with the operation of the PHIZIO platform.   The Company rents its Culver City, CA office space from a company owned by our CEO. The imputed rent expense of $500 per month is recorded in the Consolidated Statement of Operations and Additional Paid in Capital in the Balance Sheet.   The officers of the Company incur business expenses on behalf of the Company. The amounts outstanding as of June 30, 2016 and December 31, 2015 were $94,379 and $33,090, respectively.

Note 6. Income Taxes   The tax provision for interim periods is determined using an estimate of the Companys effective tax rate for the full year adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.   At June 30, 2016 and December 31, 2015, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.   The Company does not identify any material uncertain tax positions of the Company on returns that have been filed or that will be filed. The Company has not had operations and has deferred items consisting entirely of unused Net Operating Losses. Since the Company does not believe that this Net Operating Loss will ever produce a tax benefit, even if examined by taxing authorities and disallowed entirely, there would be no effect on the financial statements.   The Companys policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended June 30, 2016, and June 30, 2015, the Company did not recognize nor accrue for any interest or penalties.

Note 7. Non-Convertible Notes Payable   On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on May 1, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The fair value of the warrants is $794. For the period ended June 30, 2016, the Company recorded $2,503 of interest expense for this note.   On May 2, 2016, the Company issued a 40-day promissory note to a shareholder of $131,399 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015 and March 14, 2016. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on June 10, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The debt discount calculation for the note resulted in the fair value of the warrants being $1,251,078 and $131,399 being allocated to the note. For the period ended June 30, 2016, the Company recorded $1,641 of interest expense for this note and $118,910 for debt discount interest.   On June 11, 2016, the Company issued a 30-day promissory note to a shareholder of $152,989 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015, March 14, 2016 and May 2, 2016. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on July13, 2016. As an inducement for this promissory note, the Company issued 400,000 warrants to purchase Company common stock at $.80 per share. The debt discount calculation for the note resulted in the fair value of the warrants being $587,780 and $152,988 being allocated to the note. For the period ended June 30, 2016, the Company recorded $1,006 of interest expense for this note and $72,077 for debt discount interest. The note was renewed on July 14, 2016 as discussed in Note 12 Subsequent Events.

Note 8. Convertible Notes Payable   On February 29, 2016, a convertible promissory note with the principal value of $69,500 was converted to 227,332 shares of common stock at a conversion price of $.35 per share. The warrants associated with this note were not exercised. See Note 9 below Equity Transactions.   On June 20, 2016, the holder of the promissory note dated December 7, 2015, extended the due date from June 10, 2016 to July 11, 2016. The lender additionally agreed to extend the date required to raise additional capital as set forth in the promissory note to July 11, 2016. In exchange for this extension the Company issued 100,000 warrants to purchase Company common stock at a purchase price of $1.00 per share. The fair value of the warrants is $111,792. The extension also stipulated payment of outstanding interest of $12,000 and extension fee of $13,000. These charges were paid on June 10, 2016. On July 12, 2016, the note was extended as discussed in Note. 12 Subsequent Events.

Note 10. Commitments, Contingencies   The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business.   The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (Rule 419) of Regulation C under the Securities Act of 1933, as amended (the Securities Act) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a Blank Check offering subject to Rule 419 (the Rule 419 Offering) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the Trust Account Balance).   Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties efforts to satisfy all of the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the Share Exchange Agreement) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (Form 8A) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the Converted Offering), to be conducted pursuant to Regulation D, as promulgated under the Securities Act.   Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Companys restricted common stock in the Converted Offering (the Consent) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419.   However, pursuant to Rule 419(e)(2)(iv), funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement]. As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return.   As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419, but was unable to satisfy the SECs concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted.   As a result of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. As a result of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation.   Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining at this time the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. In light of the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Companys Balance Sheet for the $90,000 that was subject to the Consent.   The Company rents its Culver City, CA office space from a company owned by our CEO. The rental agreement provides for the value of the rent of $500 per month be recorded as contributed towards the founding eWellness and its operations. During the period ended June 30, 2016, we have recorded this rent payment in the Consolidated Statements of Operations and Additional Paid in Capital on the Balance Sheet.    On April 1, 2015, the Company entered into an Operating Agreement with Evolution Physical Therapy (EPT), a company owned by one of the Companys officers, wherein it is agreed that EPT would be able to operate the Companys telemedicine platform www.phzio.com and offer it to selected physical therapy patients of EPT. The Company is to receive 75% of the net insurance reimbursements from the patient for use of the platform. The Company will advance capital requested by EPT for costs specifically associated with operating the www.phzio,com platform and associated physical therapy treatments computer equipment, office or facilities rental payments, physical therapist or physical therapy assistant, administrative staff, patient induction equipment, office supplies, utilities and other associated operating costs. It is anticipated that the operation of the platform by EPT will generate positive cash flow within 90 days from the start of patient induction.   On May 20, 2015, the Company entered into an agreement with Mavericks Capital Securities LLC (Mavericks). The term of the contract begins on the effective date and can be terminated within 30 days upon written notice by either party. The Company is to pay Mavericks a monthly retainer fee of $10,000 that is deferred until the Company raises $250,000 in new investor funds from the effective date. In addition, the Company granted Mavericks 250,000 warrants to purchase Company common stock at $.35 per share. On September 28, 2015, the Company and Mavericks entered into an amendment to the consultant agreement pursuant to which Mavericks will also assist the Company in the acquisition of new customers, for which the Company shall pay Mavericks 10% of the revenue received by the Company, net of any pass through costs, from any such customers introduced to the Company by Mavericks; payment shall be made upon the Companys receipt of such revenues. In the amendment, the parties also further clarified the definition of Customer Acquisition.   On January 20, 2016, the Company entered into a one year agreement with a consulting firm to provide marketing and financial media awareness services. Compensation for this agreement is the issuance of 100,000 shares of common stock 50,000 were issued at the signing of the agreement and the other 50,000 are to be issued in July, 2016. As of the filing of this report, these shares have not been issued. The value of these shares is $5,000 for each issuance which is being amortized over the term of the contract.   On February 1, 2016, the Company entered into a six month agreement with a consulting firm for services including introductions to brokers, investment bankers, market makers and business development opportunities. Compensation for his agreement is the issuance of 100,000 shares of common stock. The value of these shares is $10,000 and is being amortized over the term of the contract.   On March 3, 2016, the Company entered into a six month agreement with a consulting firm for management consulting, business advisory and public relations services. Compensation for this agreement is the issuance of 100,000 shares of common stock for the purchase price of $100 and a $2,500 monthly fee that is to be accrued and not payable until the Company closes a qualified financing.   On April 13, 2016, we entered into a one-year renewable advisory agreement with Dan Mills, MPT to become the Companys chairman of the to-be-formed committee known as the eWellness Physical Therapy Clinical Advisory Board and to act as the Companys national spokesperson at the American Physical Therapy Association (APTA).   As inducement for Mr. Mills to enter the Agreement, we agreed to issue 250,000 immediately vesting common stock purchase warrants at a price of $1.00 per share. The fair value of the warrants is $503,762. The common stock underlying the warrants has piggy-back registration rights. In addition, 10,000 shares of common stock were issued with a value of $30,000. Per the agreement Mr. Mills will receive $0.50 cents per PHZIO session that an APTA members uses and $500 per month in consulting fees.   On May 23, 2016, the Company entered into a one-year agreement with a financial advisory consultant. Compensation for this agreement is the issuance of 450,000 shares of common stock that vest on January 2, 2017. The value of these shares is $1,669,500 and is being amortized over the term of the contact.    From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, the Company believes that there are no current matters that would have a material effect on the Companys financial position or results of operations.

Note 11. Derivative Valuation   The warrants granted with the $275,000 senior convertible promissory note (the Note) issued on December 7, 2015 (described in Note 8) have a Most Favored Nation clause resulting in the exercise price of the warrants not being fixed. Therefore, this feature has been characterized as a derivate liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. During the three and six months ended June 30, 2016, the outstanding fair value of the warrants accounted for as a derivative liability amounted to $782,944. As of June 30, 2016, a loss of $505,142 was recognized in the statement of operations as the change in valuation from inception.   For purposes of determining the fair market value of the derivative liability for the warrants and the convertible note, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Stock price at valuation date</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">1.75</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise price of warrants</td> <td> </td> <td>$</td> <td style="text-align: right">0.75-1.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.2-1.01</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock volatility factor</td> <td> </td> <td> </td> <td style="text-align: right">49.70-62.65</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Years to Maturity</td> <td> </td> <td> </td> <td style="text-align: right">.03-4.44 </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">None </td> <td> </td></tr> </table>

Note 12. Subsequent Events   On July 5, 2016, the Company entered into a six-month agreement with an investment and business consultant for certain investment and business matters. Compensation for this agreement is the issuance of 125,000 shares of common stock.   On July 8, 2016, the Company entered into a five year business development agreement with a consultant for marketing the Companys telemedicine platform to its customers. Upon the completion of a partnership for the Company with a large scale California employer and/or one of its affiliate institutions that includes at least a 100 patient pilot study, the Company agrees to issue 50,000 $1.00 common stock 5-year purchase warrants. For each additional licensing of 20 physical therapy professionals through the consultant, the Company will issue an additional 50,000 common stock 5-year purchase warrants priced at market at the time of issuance. For any direct investor introduced by the consultant, the Company will pay a 5% cash fee on the gross amount invested.   On July 12, 2016, the Company agreed to an extension on a promissory note dated December 7, 2015. As an inducement for the extension of this note, the Company agreed to pay a $10,000 loan extension fee and issue 300,000 warrants to purchase Company common stock at $.50 per share.   On July 13, 2016, the Company issued 172,958 shares of common stock as a result of warrants being exercised.   On July 13, 2016, the Company agreed to amend certain previous warrants granted on August 28, 2015, September 16, 2015, October 3, 2015, December 6, 2015, March 14, 2016, May 1, 2016, and June 20, 2016. The previously granted warrants had a purchase price of $.80 per share and the Company has agreed to reduce that to $.50 per share. Amendments for these warrants were issued.   On July 14, 2016, the Company issued a 30-day promissory note to a shareholder of $177,762 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015, March 14, 2016, May 2, 2016, and June 11, 2016. The amount of the note includes interest accrued on the previous notes, risky loan fee and a default fee. The note has an annual interest rate of 12% due and payable on August 15, 2016. As an inducement for this promissory note, the Company issued 300,000 warrants to purchase Company common stock at $.50 per share.

Basis of Presentation   The interim financial information of the Company as of and for the periods ended June 30, 2016 and June 30, 2015 is unaudited. The balance sheet as of December 31, 2015 is derived from audited financial statements of eWellness Healthcare Corporation. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform to the accounting policies disclosed in ASU 2014-10. In the opinion of management, all adjustments which are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that can be expected for the entire year ending December 31, 2016. The unaudited financial statements should be read in conjunction with the financial statements and the notes thereto included in the Companys annual report on Form 10-K for the year ended December 31, 2015.

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

Going Concern   For the period ended June 30, 2016, the Company has no revenues. The Company has an accumulated loss of $5,809,219. In view of these matters, there is substantive doubt about the Companys ability to continue as a going concern. The Companys ability to continue operations is dependent upon the Companys ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Loss per Common Share   The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the period ended June 30, 2016, no dilutive shares are added into the loss per share calculations.

Recent Accounting Pronouncements   From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that are adopted by the Company as of the specified date. The Company has elected to the early adoption of ASU 2015-03 that simplifies the presentation of debt issuance costs. The Company had previously used the methodology in this standard and has adopted the pronouncement for current and future debt instruments.

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 15, 2016
Document And Entity Information
Entity Registrant Name	eWELLNESS HEALTHCARE Corp
Entity Central Index Key	0001550020
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		19,675,728
Trading Symbol	EWLL
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash	$ 12,249	$ 41,951
Prepaid Expenses	1,616,202	4,053
Total current assets	1,628,451	46,004
Property & equipment, net	5,122	5,964
Intangible assets, net	18,385	19,862
TOTAL ASSETS	1,651,958	71,830
CURRENT LIABILITIES
Accounts payable and accrued expenses	372,546	248,304
Accounts payable - related party	49,702	43,717
Accrued expenses - related party	94,379	33,090
Accrued compensation	850,408	677,000
Contingent liability	90,000	90,000
Convertible debt, net of discount	180,419	309,945
Derivative liability	782,944	2,802
Short term note and liabilities	103,673	71,605
Total current liabilities	2,524,071	1,476,463
Total Liabilities	2,524,071	1,476,463
STOCKHOLDERS' DEFICIT
Preferred stock, authorized, 10,000,000 shares, $.001 par value, 0 shares issued and outstanding
Common stock, authorized 100,000,000 shares, $.001 par value, 19,377,770 and 18,170,538 issued and outstanding, respectively	19,378	18,171
Additional paid in capital	4,917,728	2,033,383
Accumulated deficit	(5,809,219)	(3,456,187)
Total Stockholders' Deficit	(872,113)	(1,404,633)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,651,958	$ 71,830

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	19,377,770	18,170,538
Common stock, shares outstanding	19,377,770	18,170,538

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
OPERATING EXPENSES
Executive compensation	$ 181,367	$ 186,000	$ 372,000	$ 372,000
General and administrative	63,643	62,284	115,169	96,872
Professional fees	727,543	149,668	838,831	240,062
Total Operating Expenses	972,553	397,952	1,326,000	708,934
Loss from Operations	(972,553)	(397,952)	(1,326,000)	(708,934)
OTHER INCOME (EXPENSE)
Gain on extinguishment of debt				11,323
Loss on derivative liability	(505,142)		(505,142)
Interest expense, related parties	(1,032)	(879)	(1,929)	(1,957)
Interest expense	(448,697)	(35,249)	(519,961)	(21,391)
Net Loss before Income Taxes	(1,927,424)	(434,080)	(2,353,032)	(720,959)
Income tax expense
Net Loss	$ (1,927,424)	$ (434,080)	$ (2,353,032)	$ (720,959)
Basic and diluted (loss) per share	$ (0.10)	$ (0.03)	$ (0.12)	$ (0.04)
Basic and diluted weighted average shares outstanding	18,671,490	16,881,000	18,986,781	16,811,276

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (2,353,032)	$ (720,959)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,319	2,109
Contributed services	192,000	195,000
Shares issued for consulting services		24,222
Imputed interest - related party	1,929	1,957
Options expense	508,395
Interest on debt extension	62,933
Amortization of debt discount to interest expense	147,650	28,944
Warrants issued for services		22,592
Warrants issued for debt extension	780,142
Rent contributed by officer	3,000
Changes in operating assets and liabilities
Advances - related parties		(7,054)
Prepaid expense	127,451	(25,726)
Accounts payable and accrued expenses	136,829	20,108
Accounts payable - related party	5,985	(10,820)
Accrued expenses - related party	61,289	24,351
Accrued compensation	173,408	174,000
Net cash used in operating activities	(149,702)	(287,169)
Cash flows from investing activities
Purchase of equipment		(4,207)
Net cash used in investing activities		(4,207)
Cash flows from financing activities
Proceeds from issuance of common stock	120,000	270,080
Promissory note		25,000
Net cash provided by financing activities	120,000	295,080
Net increase (decrease) in cash	(29,702)	3,704
Cash, beginning of period	41,951	900
Cash, end of period	12,249	4,604
Supplemental Information:
Taxes
Interest Expense

XML 18 R6.htm IDEA: XBRL DOCUMENT

The Company

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

Note 1. The Company

The Company and Nature of Business

XML 19 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Going Concern

For the period ended June 30, 2016, the Company has no revenues. The Company has an accumulated loss of $5,809,219. In view of these matters, there is substantive doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instruments

As of June 30, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative liability	$	782,944	$	-	$	-	$	782,944
Total liabilities measure at fair value	$	782,944	$	-	$	-	$	782,944

Loss per Common Share

Recent Accounting Pronouncements

XML 20 R8.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Jun. 30, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 3. Property and Equipment

XML 21 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 4. Intangible Assets

XML 22 R10.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2016

Related Party Transactions

Note 5. Related Party Transactions

The officers of the Company incur business expenses on behalf of the Company. The amounts outstanding as of June 30, 2016 and December 31, 2015 were $94,379 and $33,090, respectively.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 6. Income Taxes

XML 24 R12.htm IDEA: XBRL DOCUMENT

Non-Convertible Notes Payable

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Non-Convertible Notes Payable

Note 7. Non-Convertible Notes Payable

XML 25 R13.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Convertible Notes Payable

Note 8. Convertible Notes Payable

XML 26 R14.htm IDEA: XBRL DOCUMENT

Equity Transactions

6 Months Ended

Jun. 30, 2016

Equity [Abstract]

Equity Transactions

Note 9. Equity Transactions

Preferred Stock

Common Stock

The total number of shares of common stock which the Company shall have authority to issue is 100,000,000 shares with a par value of $0.001 per share.

On February 29, 2016, the Company authorized the issuance of 227,232 shares for conversion of convertible debt of $69,500.

On June 2, 2016, the Company sold 120,000 shares of common stock upon receipt of $120,000 cash.

As of the period ended June 30, 2016, the Company has 19,377,770 shares of common stock issued and outstanding.

On February 22, 2016, the Company received the common stock trading symbol of EWLL.

Stock Options

The following is a summary of the status of all Company’s stock options as of June 30, 2016 and changes during the six months ended on that date:

	Number		Weighted
	of Stock		Average
	Options		Exercise Price
Oustanding at January 1, 2016		0	$	-
Granted		3,100,000	$	0.82
Exercised		0	$	-
Cancelled		0	$	-
Outstanding at June 30, 2016		3,100,000	$	0.82
Options exercisable at June 30, 2016		3,100,000	$	0.82

Warrants

On June 2, 2016, the Company authorized the issuance of 60,000 warrants that were issued as part of a stock purchase agreement for $120,000.

The following is a summary of the status of all of the Company’s warrants as of June 30, 2016 and changes during the six months ended on that date:

			Weighted
	Number of		Average
	Warrants		Exercise Price
Outstanding at January 1, 2015		609,533	$	0.35
Granted		5,021,658	$	0.63
Exercised		-	$	-
Cancelled		-	$	-
Outstanding at December 31, 2015		5,631,191	$	0.61
Granted		1,360,000	$	0.85
Exercised		-	$	-
Cancelled		-	$	-
Outstanding at June 30, 2016		6,991,191	$	0.65

Stock price on the valuation date	$	2.00-3.75
Exercise price of warrants	$	.80 and 1.00
Dividend yield		0.00	%
Years to maturity		1-5
Risk free rate		1.06%-1.32	%
Expected volatility		61.41%-63.40	%

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments, Contingencies

Note 10. Commitments, Contingencies

XML 28 R16.htm IDEA: XBRL DOCUMENT

Derivative Valuation

6 Months Ended

Jun. 30, 2016

Derivative Valuation

Derivative Valuation

Note 11. Derivative Valuation

Stock price at valuation date	$	1.75
Exercise price of warrants	$	0.75-1.00
Risk free interest rate		0.2-1.01	%
Stock volatility factor		49.70-62.65	%
Years to Maturity		.03-4.44
Expected dividend yield		None

XML 29 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

Note 12. Subsequent Events

On July 13, 2016, the Company issued 172,958 shares of common stock as a result of warrants being exercised.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Going Concern

Fair Value of Financial Instruments

As of June 30, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative liability	$	782,944	$	-	$	-	$	782,944
Total liabilities measure at fair value	$	782,944	$	-	$	-	$	782,944

Loss per Common Share

Recent Accounting Pronouncements

XML 31 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Property, Plant and Equipment [Abstract]

Summary of Assets and Liabilities Fair Value Recurring Basis

As of June 30, 2016, the Company had the following assets and liabilities measured at fair value on a recurring basis.

	Total		Level 1		Level 2		Level 3
Derivative liability	$	782,944	$	-	$	-	$	782,944
Total liabilities measure at fair value	$	782,944	$	-	$	-	$	782,944

XML 32 R20.htm IDEA: XBRL DOCUMENT

Equity Transactions (Tables)

6 Months Ended

Jun. 30, 2016

Equity [Abstract]

Summary of Stock Options Activity

The following is a summary of the status of all Company’s stock options as of June 30, 2016 and changes during the six months ended on that date:

	Number		Weighted
	of Stock		Average
	Options		Exercise Price
Oustanding at January 1, 2016		0	$	-
Granted		3,100,000	$	0.82
Exercised		0	$	-
Cancelled		0	$	-
Outstanding at June 30, 2016		3,100,000	$	0.82
Options exercisable at June 30, 2016		3,100,000	$	0.82

Schedule of Warrant Activity

The following is a summary of the status of all of the Company’s warrants as of June 30, 2016 and changes during the six months ended on that date:

			Weighted
	Number of		Average
	Warrants		Exercise Price
Outstanding at January 1, 2015		609,533	$	0.35
Granted		5,021,658	$	0.63
Exercised		-	$	-
Cancelled		-	$	-
Outstanding at December 31, 2015		5,631,191	$	0.61
Granted		1,360,000	$	0.85
Exercised		-	$	-
Cancelled		-	$	-
Outstanding at June 30, 2016		6,991,191	$	0.65

Schedule of Valuation Assumptions

The significant assumptions used in the Black Scholes valuation of the date of issuance are as follows:

Stock price on the valuation date	$	2.00-3.75
Exercise price of warrants	$	.80 and 1.00
Dividend yield		0.00	%
Years to maturity		1-5
Risk free rate		1.06%-1.32	%
Expected volatility		61.41%-63.40	%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 33 R21.htm IDEA: XBRL DOCUMENT

Derivative Valuation (Tables)

6 Months Ended

Jun. 30, 2016

Derivative Valuation Tables

Schedule of Assumptions Used Black Scholes Valuation of Derivative

The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

Stock price at valuation date	$	1.75
Exercise price of warrants	$	0.75-1.00
Risk free interest rate		0.2-1.01	%
Stock volatility factor		49.70-62.65	%
Years to Maturity		.03-4.44
Expected dividend yield		None

XML 34 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Accumulated deficit	$ 5,809,219	$ 3,456,187

XML 35 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value Recurring Basis (Details)	Jun. 30, 2016 USD ($)
Derivative liability	$ 782,944
Total liabilities measure at fair value	782,944
Level 1 [Member]
Derivative liability
Total liabilities measure at fair value
Level 2 [Member]
Derivative liability
Total liabilities measure at fair value
Level 3 [Member]
Derivative liability	782,944
Total liabilities measure at fair value	$ 782,944

XML 36 R24.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Property and equipment	$ 5,122		$ 5,122		$ 5,964
Depreciation expense	421	$ 632	842	$ 632
Computer Equipment [Member]
Property and equipment	8,421		8,421		8,421
Accumulated depreciation	$ 3,299		$ 3,299		$ 2,457

XML 37 R25.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Intangible assets	$ 18,385		$ 18,385		$ 19,862
Amortization expense	739	$ 977	1,477	$ 1,477
SoftwareLlicense [Member]
Intangible assets	24,770		24,770		24,770
Accumulated amortization	$ 6,385		$ 6,385		$ 4,908

XML 38 R26.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015	Mar. 31, 2015
Accounts payable-related party	$ 49,702		$ 49,702			$ 43,717
Imputed interest - related party	$ 1,032	$ 879	$ 1,929	$ 1,957
Percentage of interest rate of related party	8.00%		8.00%				8.00%
Percenage of patient insurance reimbursements received			75.00%
Rent expense			$ 500
Accrued expenses - related party	$ 94,379		94,379			$ 33,090
Chief Financial Officer [Member]
Amount paid by related parties	$ 101,171		$ 101,171
Chief Marketing Officer [Member]
License fee					$ 20,000

XML 39 R27.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	6 Months Ended
Income Taxes (Details Narrative) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets, net valuation allowance
Interest or penalties

XML 40 R28.htm IDEA: XBRL DOCUMENT

Non-Convertible Notes Payable (Details Narrative) - USD ($)					3 Months Ended	6 Months Ended
	Jun. 11, 2016	Jun. 10, 2016	May 02, 2016	Mar. 14, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Fair value of warrants					$ 782,944	$ 782,944
Debt discount note						147,650	$ 28,944
Interest expense note		$ 12,000				62,933
Non-Convertible Notes Payable1 [Member]
Promisory notes payable				$ 112,550
Promisory note payable description				On March 14, 2016, the Company issued a 45-day promissory note to a shareholder of $112,550 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, and December 6, 2015.
Debt instrumenst interest rate				12.00%
Debt instruments maturity date				May 01, 2016
Issuance of warrants to purchase of common stock				400,000
Warrants issuance price per share				$ .80
Fair value of warrants				$ 794
Interest expense note						2,503
Non-Convertible Notes Payable2 [Member]
Promisory notes payable			$ 131,399
Promisory note payable description			On May 2, 2016, the Company issued a 40-day promissory note to a shareholder of $131,399 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015 and March 14, 2016.
Debt instrumenst interest rate			12.00%
Debt instruments maturity date			Jun. 10, 2016
Issuance of warrants to purchase of common stock			400,000
Warrants issuance price per share			$ .80
Fair value of warrants			$ 1,251,078
Debt discount note			$ 131,399			118,910
Interest expense note						1,641
Non-Convertible Notes Payable3 [Member]
Promisory notes payable	$ 152,989
Promisory note payable description	On June 11, 2016, the Company issued a 30-day promissory note to a shareholder of $152,989 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015, March 14, 2016 and May 2, 2016
Debt instrumenst interest rate	12.00%
Debt instruments maturity date	Jul. 03, 2016
Issuance of warrants to purchase of common stock	400,000
Warrants issuance price per share	$ .80
Fair value of warrants	$ 578,780
Debt discount note	$ 152,988					72,077
Interest expense note						$ 1,006
Note renewed date	Jul. 14, 2016

XML 41 R29.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Narrative) - USD ($)					3 Months Ended	6 Months Ended
Convertible Notes Payable (Details Narrative) - USD ($)	Jun. 20, 2016	Jun. 10, 2016	Jun. 02, 2016	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jul. 08, 2016
Converted debt into shares amount				$ 69,500
Number of converted common stock				227,232
Purchase of common stock purchase price per share								$ 1.00
Fair value of warrants					$ 782,944	$ 782,944
Interest expense		$ 12,000				$ 62,933
Extension fee		13,000
Warrant [Member]
Fair value of warrants		$ 111,792	$ 120,000
Convertible Notes Payable [Member]
Converted debt into shares amount				$ 69,500
Number of converted common stock				227,332
Common stock conversion price per share				$ .35
Convertible Notes Payable [Member] \| Warrant [Member]
Debt instruments maturity date	Jul. 11, 2016
Warrants to purchase of common stock shares	100,000
Purchase of common stock purchase price per share	$ 1.00
Fair value of warrants	$ 111,792

XML 42 R30.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details Narrative) - USD ($)							3 Months Ended	6 Months Ended
Equity Transactions (Details Narrative) - USD ($)	Jun. 10, 2016	Jun. 02, 2016	May 23, 2016	Apr. 25, 2016	Feb. 29, 2016	Feb. 19, 2016	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Aug. 06, 2015
Preferred stock, shares authorized							10,000,000	10,000,000	10,000,000
Preferred stock, par value							$ .001	$ .001	$ .001
Preferred stock, shares issued							0	0	0
Common stock, shares authorized							100,000,000	100,000,000	100,000,000
Common stock, par value							$ 0.001	$ 0.001	$ 0.001
Shares issued during period for conversion of convertible debt, shares					227,232
Shares issued during period for conversion of convertible debt					$ 69,500
Shares issued during period for consulting services, shares			450,000					860,000
Shares weighted average price per share							$ 2.023	$ 2.023
Number of common stock shares sold in cash during the period		120,000
Number of common stock sold in cash during the period		$ 120,000
Common stock, shares issued							19,377,770	19,377,770	18,170,538
Common stock, shares outstanding							19,377,770	19,377,770	18,170,538
Fair value of warrants							$ 782,944	$ 782,944
Warrant [Member]
Number of warrants issued as part of extension of promissory note	100,000	60,000
Fair value of warrants	$ 111,792	$ 120,000
Warrant [Member]
Number of warrants issued as part of extension of promissory note								1,200,000
Fair value of warrants								$ 1,839,652
Stock Option Plan [Member]
Number of reserved shares available for grants										3,000,000
Percentage of outstanding shares diluted basis										2.00%
Number of stock option vested upon grant date						2,850,000
Stock options vest to purchase shares of common stock price per share						$ 0.80
Risk free rate						0.84%
Volatility rate						61.40%
Vested value of options								4,633
Stock Option Plan1 [Member]
Number of stock option vested upon grant date				250,000
Stock options vest to purchase shares of common stock price per share				$ 1.00
Risk free rate				0.53%
Volatility rate				57.20%
Vested value of options								$ 503,762

XML 43 R31.htm IDEA: XBRL DOCUMENT

Equity Transactions - Summary of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2016 $ / shares shares
Equity [Abstract]
Number of Stock Options Oustanding , Beginning Balance \| shares	0
Number of Stock Options Oustanding , Granted \| shares	3,100,000
Number of Stock Options Oustanding , Exercised \| shares	0
Number of Stock Options Oustanding , Cancelled \| shares	0
Number of Stock Options Oustanding , Ending Balance \| shares	3,100,000
Number of Stock Options Oustanding , Exercisable \| shares	3,100,000
Weighted Average Exercise Price, Beginning \| $ / shares
Weighted Average Exercise Price, Granted \| $ / shares	0.82
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Cancelled \| $ / shares
Weighted Average Exercise Price, Ending \| $ / shares	0.82
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 0.82

XML 44 R32.htm IDEA: XBRL DOCUMENT

Equity Transactions - Summary of Warrant Activity (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Number of Warrants Outstanding, Beginning Balance	5,631,191	609,533
Number of Warrants Granted	1,360,000	5,021,658
Number of Warrants Exercised
Number of Warrants Cancelled
Number of Warrants outstanding, Ending Balance	6,991,191	5,631,191
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 0.61	$ 0.35
Weighted Average Exercise Price, Warrants Granted	0.85	0.63
Weighted Average Exercise Price, Warrants Exercised
Weighted Average Exercise Price, Warrants Cancelled
Weighted Average Exercise Price, Warrants outstanding, Ending Balance	$ 0.65	$ 0.61

XML 45 R33.htm IDEA: XBRL DOCUMENT

Equity Transactions - Schedule of Valuation Assumptions (Details) - $ / shares	6 Months Ended
	Jun. 30, 2016	Jul. 08, 2016
Stock price on the valuation date	$ 1.75
Exercise price of warrants		$ 1.00
Dividend yield	0.00%
Minimum [Member]
Stock price on the valuation date	$ 2.00
Exercise price of warrants	$ 0.8
Years to maturity	1 year
Risk free rate	1.06%
Expected volatility	61.41%
Maximum [Member]
Stock price on the valuation date	$ 3.75
Exercise price of warrants	$ 1.00
Years to maturity	5 years
Risk free rate	1.32%
Expected volatility	63.40%

XML 46 R34.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies (Details Narrative) - USD ($)									3 Months Ended	6 Months Ended
	Jul. 08, 2016	May 23, 2016	Mar. 03, 2016	Feb. 01, 2016	Jan. 20, 2016	Sep. 28, 2015	May 20, 2015	Apr. 02, 2015	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Percentage of returned funds									90.00%	90.00%
Percentage of funds proceed									10.00%	10.00%
Percentage of required funds									90.00%	90.00%
Escrowed funds									$ 100,000	$ 100,000
Proceeds from escrowed funds										10,000
Return of escrowed funds										90,000
Contingent liability									90,000	90,000	$ 90,000
Rent expense										$ 500
Percentage of insurance reimbursement								75.00%
Issuance of warrants to purchase of commn stock shares	50,000
Warrants price per share	$ 1.00
Consulting agreement term		1 year
Shares issued during period for consulting services, shares		450,000								860,000
Shares issued during period for consulting services		$ 1,669,500
Fair value of warrants									$ 782,944	$ 782,944
Mr. Mills [Member]
Consulting fee										$ 500
Issuance of warrants to purchase of commn stock shares										250,000
Warrants price per share									$ 1.00	$ 1.00
Shares issued during period for consulting services, shares										30,000
Fair value of warrants										$ 503,762
Common stock issued price per share									$ 0.50	$ 0.50
Mavericks Capital Securities Llc [Member]
Consulting fee							$ 10,000
Proceeds from related party							$ 250,000
Issuance of warrants to purchase of commn stock shares							250,000
Warrants price per share							$ 0.35
Percentage of revenue received						10.00%
Escrow Trust [Member]
Percentage of subscription proceeds									10.00%	10.00%
Trust account balance									$ 90,000	$ 90,000
Consulting Firm [Member]
Consulting fee			$ 2,500
Consulting agreement term			6 months	6 months	1 year
Shares issued during period for consulting services, shares			100,000	100,000	100,000
Shares issued during period for consulting services			$ 100	$ 10,000	$ 5,000
Consulting Firm [Member] \| Consulting Services Agreement [Member]
Shares issued during period for consulting services, shares					50,000
Consulting Firm [Member] \| Consulting Services Agreement [Member] \| July, 2016 [Member]
Shares issued during period for consulting services, shares					50,000

XML 47 R35.htm IDEA: XBRL DOCUMENT

Derivate Valuation (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
Derivate Valuation (Details Narrative) - USD ($)	Dec. 07, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Derivative Valuation
Warrants granted	$ 275,000
Fair value of warrants		$ 782,944		$ 782,944
Loss on derivative liability		$ 505,142		$ 505,142

XML 48 R36.htm IDEA: XBRL DOCUMENT

Derivate Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)	6 Months Ended
	Jun. 30, 2016 $ / shares
Stock price at valuation date	$ 1.75
Expected dividend yield	0.00%
Minimum [Member]
Stock price at valuation date	$ 2.00
Exercise price of warrants	$ 0.75
Risk free interest rate	0.20%
Stock volatility factor	49.70%
Years to Maturity	3 months 18 days
Maximum [Member]
Stock price at valuation date	$ 3.75
Exercise price of warrants	$ 1.00
Risk free interest rate	1.01%
Stock volatility factor	62.65%
Years to Maturity	4 years 5 months 9 days

XML 49 R37.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	Jul. 14, 2016	Jul. 13, 2016	Jul. 12, 2016	Jul. 08, 2016	Jul. 05, 2016	Jun. 10, 2016	Jun. 02, 2016	Jun. 30, 2016
Number of common stock shares issued during the period							120,000
Issuance of warrants to purchase of commn stock shares				50,000
Warrants price per share				$ 1.00
Warrant term				5 years
Additional number of warrant purchase to common stock				50,000
Loan extension fee						$ 13,000
Minimum [Member]
Warrants price per share								$ 0.8
Subsequent Event [Member]
Number of common stock shares issued during the period					125,000
Issuance of warrants to purchase of commn stock shares			300,000
Warrants price per share		$ .80
Loan extension fee			$ 10,000
Debt instrument maturity date			Dec. 07, 2015
Number of warrant to common stock share exercised		172,958
Warrant purchase description		On July 13, 2016, the Company agreed to amend certain previous warrants granted on August 28, 2015, September 16, 2015, October 3, 2015, December 6, 2015, March 14, 2016, May 1, 2016, and June 20, 2016
Subsequent Event [Member] \| Promissory Note Extension [Member]
Issuance of warrants to purchase of commn stock shares	300,000
Warrants price per share	$ .50
Debt instrument maturity date	Aug. 15, 2016
Promisory notes payable	$ 177,762
Promisory note payable description	On July 14, 2016, the Company issued a 30-day promissory note to a shareholder of $177,762 as an extension for notes with a shareholder dated May 30 2015, July 15, 2015, September 16, 2015, October 11, 2015, December 6, 2015, March 14, 2016, May 2, 2016, and June 11, 2016.
Debt instrumenst interest rate	12.00%
Subsequent Event [Member] \| Minimum [Member]
Warrants price per share		$ .50

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end

Equity Transactions - Summary of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2016 $ / shares shares
Equity [Abstract]
Number of Stock Options Oustanding , Beginning Balance \| shares	0
Number of Stock Options Oustanding , Granted \| shares	3,100,000
Number of Stock Options Oustanding , Exercised \| shares	0
Number of Stock Options Oustanding , Cancelled \| shares	0
Number of Stock Options Oustanding , Ending Balance \| shares	3,100,000
Number of Stock Options Oustanding , Exercisable \| shares	3,100,000
Weighted Average Exercise Price, Beginning \| $ / shares
Weighted Average Exercise Price, Granted \| $ / shares	0.82
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Cancelled \| $ / shares
Weighted Average Exercise Price, Ending \| $ / shares	0.82
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 0.82